Aromatase inhibitors and postmenopausal breast cancer patients with tamoxifen-induced endometrial pathology

Clinical Cancer Research

Volumn 12, Issue 18, 2006, Pages 5603-

  Morales, Leilani ^a   Paridaens, Robert ^a   Timmerman, Dirk ^a   Neven, Patrick ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; EXEMESTANE; LETROZOLE; TAMOXIFEN;

BREAST CANCER; CURETTAGE; DRUG SUBSTITUTION; ENDOMETRIAL DISEASE; HUMAN; HYSTEROSCOPY; LETTER; LONG TERM CARE; POSTMENOPAUSE; PRIORITY JOURNAL; TRANSVAGINAL ECHOGRAPHY; UTERUS MALFORMATION; VAGINA BLEEDING;

ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; DIAGNOSIS, DIFFERENTIAL; ENDOMETRIUM; FEMALE; HUMANS; POSTMENOPAUSE; TAMOXIFEN; UTERINE DISEASES;

EID: 33749331845     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-0897     Document Type: Letter

References (5)

1. Gerber B, Krause A, Reimer T, et al. Anastrozole versus tamoxifen treatment in postmenopausal women with endocrine-responsive breast cancer and tamoxifen-induced endometrial pathology. Clin Cancer Res 2006;12:1245-50.
2. Morales L, Timmerman D, Neven P, et al. Third generation aromatase inhibitors may prevent endometrial growth and reverse tamoxifen-induced uterine changes in postmenopausal breast cancer patients. Ann Oncol 2005;16:70-5.
3. Garrone O, Ortu S, Occelli M, et al. Reversal of tamoxifen induced endometrial modifications by switching to letrozole: a prospective transvaginal ultrasound (TVUS) study in early breast cancer patients [abstract 276]. Proc Am Soc Clin Oncol 2003;22:69.
4. Bertelli G, Hall E, Bliss JM, et al. Intergroup Exemestane Study: results of the endometrial sub-protocol [abstract 402]. Breast Cancer Res Treat 2004;88 Suppl 1:S35.
5. Amant F, Moerman P, Neven P, et al. Endometrial cancer. Lancet 2005;366:491-505.